West Pharmaceutical Services (NYSE:WST) Updates FY 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 8.850-9.050 for the period, compared to the consensus estimate of 8.610. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.3 billion. West Pharmaceutical Services also updated its Q3 2026 guidance to 2.140-2.240 EPS.

West Pharmaceutical Services Stock Down 0.9%

NYSE:WST opened at $355.25 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The company has a market capitalization of $25.10 billion, a price-to-earnings ratio of 47.49, a price-to-earnings-growth ratio of 2.90 and a beta of 1.16. West Pharmaceutical Services has a one year low of $223.83 and a one year high of $386.00. The stock has a 50-day simple moving average of $336.51 and a 200 day simple moving average of $287.14.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.West Pharmaceutical Services’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Sell-side analysts predict that West Pharmaceutical Services will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is currently 11.76%.

Analysts Set New Price Targets

WST has been the subject of several recent research reports. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Morgan Stanley increased their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Stephens reiterated an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 target price for the company. Finally, Evercore reissued an “outperform” rating and issued a $410.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $363.17.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by insiders.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West Pharmaceutical beat Q2 estimates on both earnings and revenue, reporting $2.37 EPS versus $2.08 expected and $872.3 million in sales versus $840.0 million expected. West Reports Second-Quarter 2026 Results
• Positive Sentiment: The company lifted full-year 2026 guidance, now projecting EPS of $8.85-$9.05 and revenue of $3.3 billion-$3.4 billion, both above prior expectations. Reuters article on raised annual forecast
• Positive Sentiment: Management highlighted strong HVP growth and momentum from GLP-1 and biologics-related demand, suggesting the growth trend may continue into the back half of the year. TipRanks guidance summary
• Neutral Sentiment: West also issued modestly ahead Q3 guidance, with EPS of $2.14-$2.24 and revenue of $820 million-$835 million, reinforcing the view that performance remains solid rather than signaling a dramatic acceleration.
• Negative Sentiment: Earlier coverage had suggested the stock looked expensive relative to fair value, so some investors may still worry the rally leaves limited upside if growth slows. Yahoo Finance article on valuation

Institutional Trading of West Pharmaceutical Services

A number of large investors have recently added to or reduced their stakes in the business. DV Equities LLC acquired a new position in shares of West Pharmaceutical Services in the 4th quarter worth $28,000. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at $25,000. Meeder Asset Management Inc. raised its holdings in West Pharmaceutical Services by 1,023.5% during the 4th quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 174 shares during the period. MUFG Securities EMEA plc acquired a new position in shares of West Pharmaceutical Services in the second quarter worth about $47,000. Finally, State of Wyoming purchased a new position in shares of West Pharmaceutical Services in the second quarter worth approximately $49,000. 93.90% of the stock is currently owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.